Motif Bio plc Appoints Westwicke Partners As Investor Relations Adviser In U.S.

Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that it has appointed Westwicke Partners as its investor relations adviser in the U.S. Westwicke Partners provides strategic investor relations and capital markets advisory services exclusively to public and private companies in the healthcare sector.

Graham Lumsden, CEO of Motif, said: "We look forward to building a relationship with the Westwicke team and to leveraging their experience as we continue to move our clinical development programs forward".

Enquiries

Motif Bio plc.
Graham Lumsden (Chief Executive Officer)
Robert Bertoldi (Chief Financial Officer)
www.motifbio.com
info@motifbio.com

MC Services AG (TRADE PR)
Raimund Gabriel
Shaun Brown
+49 (0) 89 210 2280
+44 (0) 207 148 5998

Zeus Capital Partners Limited (BROKER and NOMAD)
+44 (0) 20 3709 0142
Phil Walker/ John Treacy
Dominic Wilson

Northland Capital Partners Limited (BROKER)
+44 (0) 20 7382 1100
Patrick Claridge/ David Hignell
John Howes/ Mark Treharne (Broking)

Plumtree Capital Limited (FINANCIAL ADVISOR)
+44 (0) 207 183 2493
Stephen Austin

Yellow Jersey PR Limited (FINANCIAL PR)
Dominic Barretto
Philip Ranger
Charles Goodwin
+44 (0) 7768 537 739

Help employers find you! Check out all the jobs and post your resume.